Scarica l'app Stockscreener
0.14
9.21%
-0.0142
Dopo l'orario di chiusura:
.14
Gossamer Bio Inc Borsa (GOSS) Ultime notizie
Gossamer Bio (GOSS) Stock Sees Fair Value Cut As Analysts Split On Seralutinib - Yahoo Finance
GOSS Maintained by Piper Sandler -- Price Target Lowered to $4.0 - GuruFocus
Gossamer Bio Inc (GOSS) News, Articles, Events & Latest Updates - Stocktwits
GOSS|Gossamer Bio Inc|Price:0.154|Chg%:-0.016 - TradingKey
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update - BioSpace
$Gossamer Bio (GOSS.US)$ This is the bottom - Moomoo
Gossamer Bio: Q2 Earnings Snapshot - AOL.com
Gossamer Bio Q2 Results: EPS beats estimate, sales up 78% vs view - scanx.trade
Is Gossamer Bio Inc (GOSS) Undervalued After Q2 Earnings Beat? G - GuruFocus
Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Gossamer Bio, Inc. 2026: Revenue $9.24M, Net income $16.9M, EPS ($0.08) — 10-Q Summary - TradingView
Gossamer Bio reports Q2 2026 net income of $16.9M; cash $57.0M, NDA submission for seralutinib on track - TradingView
Gossamer Bio (GOSS) cuts debt but flags going concern and liquidity strain - Stock Titan
Gossamer Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits
MSN Money - MSN
GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
Gossamer Bio Inc (GOSS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gossamer Bio Company Profile & Introduction - Moomoo
Gossamer Bio Inc (GOSS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm - Morningstar
Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio - The National Law Review
Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Gro - The National Law Review
gossamer bio inc. Earnings dates - RTTNews
Gossamer Bio Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Gossamer Bio (GOSS) Could Be 96% Undervalued After Its Seralutinib NDA Update - Yahoo Finance
Opaleye group (NASDAQ: GOSS) reports 24.9M-share, 5.10% Gossamer Bio position - Stock Titan
$Gossamer Bio (GOSS.US)$ call me crazy but atlease you calling... - Moomoo
GOSS Upgraded by Leerink Partners -- Rating Changed to Outperform - GuruFocus
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Leerink Partners Upgrades Gossamer Bio to Outperform From Market Perform, $1 Price Target - marketscreener.com
Leerink upgrades Gossamer Bio stock rating on FDA feedback By Investing.com - Investing.com UK
Gossamer Bio (NASDAQ:GOSS) Shares Surge as FDA Progress Highlights Path Forward; Cash Covenant Looms as Next Hurdle - TechStock²
Update: Gossamer Bio Extends Gains Pre-Bell Following New Drug Application Filing Plans for Pulmonary Arterial Hypertension Treatment - Moomoo
Leerink Partners Upgrades Gossamer Bio(GOSS.US) to Buy Rating, Cuts Target Price to $1 - Moomoo
GOSS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $2.00 - GuruFocus
12 Health Care Stocks Moving In Monday's After-Market SessionGossamer Bio (NASDAQ:GOSS), ProMIS Neuros - Benzinga
Gossamer Bio Plans September 2026 Seralutinib NDA After FDA Meeting - Quiver Quantitative
Gossamer Reacquires Global Seralutinib Rights From Chiesi, Receives $5 Million - TradingView
Gossamer Bio shares surge after FDA filing update; cash concerns and dilution still loom - TechStock²
GOSS: Key Regulatory and Corporate Developments Announced - GuruFocus
Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate - Benzinga
GOSS, Gossamer Bio Updates on Seralutinib and Strategic Developm - GuruFocus
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Gossamer Bio shares jump after FDA update and seralutinib rights return - Yahoo Finance
Gossamer Bio stock surges 25% on FDA regulatory update By Investing.com - Investing.com UK
Gossamer Bio stock surges 25% on FDA regulatory update - Investing.com
Gossamer Bio (GOSS) Investor update Summary - Quartr
Why is Gossamer Bio stock surging today? By Investing.com - Investing.com Canada
Gossamer Bio plans September NDA submission for seralutinib By Investing.com - Investing.com Nigeria
Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update - Business Wire
Gossamer Bio Inc (GOSS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Gossamer Bio Inc (GOSS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Gossamer Bio plans September NDA submission for seralutinib - Investing.com
Gossamer Bio Inc (GOSS) Balance Sheet - TradingKey
Gossamer Bio Inc (GOSS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
$Gossamer Bio (GOSS.US)$ - Moomoo
GOSS|Gossamer Bio Inc|Price:0.147|Chg%:+0.011 - TradingKey
Gossamer Bio Inc (GOSS) Income Statement - TradingKey
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):